PubMed ID:
36898736
Public Release Type:
Journal
Publication Year: 2023
DOI:
https://doi.org/10.1136/jitc-2022-006570
Authors:
Caulfield Jasmine I, Aizenbud Lilach, Perdigoto Ana Luisa, Meffre Eric, Jilaveanu Lucia, Michalek Dominika A, Rich Stephen S, Aizenbud Yariv, Adeniran Adebowale, Herold Kevan C, Austin Matthew R, Kluger Harriet
Request IDs:
20431
,
23054
,
23168
Studies:
Type 1 Diabetes Genetics Consortium
Immune checkpoint inhibitors (ICIs) have dramatically improved survival in patients with cancer but are often accompanied by severe immune-related adverse events (irAEs), which can sometimes be irreversible. Insulin-dependent diabetes is a rare, but life-altering irAE. Our purpose was to determine whether recurrent somatic or germline mutations are observed in patients who develop insulin-dependent diabetes as an irAE.